Published in Oligonucleotides on January 01, 2006
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Oligonucleotide Therapies: The Past and the Present. Hum Gene Ther (2015) 0.91
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem (2014) 0.84
Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors. PLoS One (2011) 0.83
Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors. J Nucleic Acids (2012) 0.83
Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice. Nucleic Acid Ther (2014) 0.81
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. Theranostics (2011) 0.80
Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. Cancer Biol Ther (2008) 0.80
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. Nucleic Acids Res (2016) 0.78
Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. Mol Ther (2017) 0.77
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice. Mol Ther Nucleic Acids (2016) 0.76
Quantum mechanical studies of DNA and LNA. Nucleic Acid Ther (2014) 0.75
Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers. Nucleic Acids Res (2015) 0.75
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
Developing microRNA therapeutics. Circ Res (2012) 2.58
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med (2014) 2.06
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J (2011) 1.84
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem (2002) 1.57
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos (2003) 1.57
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol (2008) 1.42
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos (2006) 1.27
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci (2004) 1.20
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol (2013) 1.16
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol (2011) 1.15
Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol (2012) 1.10
Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther (2012) 1.10
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet (2009) 1.02
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther (2002) 1.02
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2002) 1.01
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis (2013) 1.00
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology (2009) 1.00
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol (2002) 0.99
Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol (2006) 0.93
Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol (2012) 0.92
Oral delivery of antisense oligonucleotides in man. J Pharm Sci (2008) 0.91
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. J Med Chem (2005) 0.90
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res (2002) 0.90
Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. Oligonucleotides (2004) 0.88
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci (2004) 0.83
Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci (2002) 0.83
Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology (2012) 0.83
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res (2003) 0.83
Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther (2007) 0.83
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res (2002) 0.83
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol (2009) 0.82
CpG and Non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice. J Immunotoxicol (2006) 0.80
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs (2005) 0.80
Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid. Toxicol Appl Pharmacol (2002) 0.79
Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides. Curr Opin Drug Discov Devel (2004) 0.79
In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides (2010) 0.79
Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther (2014) 0.79
Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue. Eur J Mass Spectrom (Chichester, Eng) (2005) 0.78
The Oligonucleotide Safety Working Group (OSWG). Nucleic Acid Ther (2012) 0.78
Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. Birth Defects Res B Dev Reprod Toxicol (2006) 0.76
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev (2003) 0.76
More on science and politics. Science (2003) 0.75
Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice. J Immunotoxicol (2006) 0.75
Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. Birth Defects Res B Dev Reprod Toxicol (2004) 0.75
Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Birth Defects Res B Dev Reprod Toxicol (2004) 0.75